HRP20191606T1 - Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij - Google Patents

Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij Download PDF

Info

Publication number
HRP20191606T1
HRP20191606T1 HRP20191606T HRP20191606T1 HR P20191606 T1 HRP20191606 T1 HR P20191606T1 HR P20191606 T HRP20191606 T HR P20191606T HR P20191606 T1 HRP20191606 T1 HR P20191606T1
Authority
HR
Croatia
Prior art keywords
methyl
ethyl
chroman
amino
naphthalen
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Manojkumar Ramprasad Shukla
Ankush Gangaram Sarde
Rajeshkumar Maganlal Loriya
Vipul Dilip Pachpute
Navnath Bajirao Walke
Talha Hussain Khan
Sanjeev Anant Kulkarni
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of HRP20191606T1 publication Critical patent/HRP20191606T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
HRP20191606 2012-02-24 2013-02-22 Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij HRP20191606T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators
EP13712928.4A EP2817299B1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
HRP20191606T1 true HRP20191606T1 (hr) 2019-12-13

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191606 HRP20191606T1 (hr) 2012-02-24 2013-02-22 Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij

Country Status (44)

Country Link
US (3) US9163001B2 (enExample)
EP (1) EP2817299B1 (enExample)
JP (1) JP6114316B2 (enExample)
KR (1) KR102041154B1 (enExample)
CN (1) CN104350047B (enExample)
AP (1) AP2014007919A0 (enExample)
AR (1) AR090135A1 (enExample)
AU (1) AU2013223715B2 (enExample)
BR (1) BR112014021133B1 (enExample)
CA (1) CA2864332C (enExample)
CL (1) CL2014002218A1 (enExample)
CO (1) CO7160018A2 (enExample)
CR (1) CR20140424A (enExample)
CU (1) CU24325B1 (enExample)
CY (1) CY1122017T1 (enExample)
DK (1) DK2817299T3 (enExample)
DO (1) DOP2014000193A (enExample)
EA (1) EA026940B9 (enExample)
ES (1) ES2743492T3 (enExample)
GE (2) GEAP201813579A (enExample)
GT (1) GT201400179A (enExample)
HR (1) HRP20191606T1 (enExample)
HU (1) HUE046172T2 (enExample)
IL (1) IL234252A (enExample)
IN (1) IN2014MN01672A (enExample)
LT (1) LT2817299T (enExample)
MA (1) MA35937B1 (enExample)
MX (1) MX355670B (enExample)
MY (1) MY171374A (enExample)
NI (1) NI201400094A (enExample)
NZ (1) NZ628627A (enExample)
PE (1) PE20142281A1 (enExample)
PH (1) PH12014501891B1 (enExample)
PL (1) PL2817299T3 (enExample)
PT (1) PT2817299T (enExample)
RS (1) RS59172B1 (enExample)
SG (1) SG11201405117SA (enExample)
SI (1) SI2817299T1 (enExample)
SM (1) SMT201900506T1 (enExample)
TN (1) TN2014000352A1 (enExample)
TW (1) TWI617549B (enExample)
UA (1) UA112679C2 (enExample)
WO (1) WO2013124828A1 (enExample)
ZA (1) ZA201405990B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014021133B1 (pt) * 2012-02-24 2022-06-28 Lupin Limited Composto e composição farmacêutica
WO2014033604A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
US12421204B2 (en) 2019-11-19 2025-09-23 Lupin Limited Process for preparing chroman compounds
JP7720306B2 (ja) * 2019-12-27 2025-08-07 ルピン・リミテッド CaSRモジュレーターの医薬組成物ならびにその方法および使用
BR112022013865A2 (pt) * 2020-01-17 2022-09-13 Lupin Ltd Métodos e composto
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020018B1 (en) * 1979-05-19 1983-06-01 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト
PT1882684E (pt) 2005-05-19 2015-02-10 Astellas Pharma Inc Derivado de pirrolidina ou um seu sal
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
EP2079525A1 (en) * 2006-10-26 2009-07-22 Amgen Inc. Calcium receptor modulating agents
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
JP5478496B2 (ja) * 2007-10-15 2014-04-23 アムジエン・インコーポレーテツド カルシウム受容体調節剤
AU2008328362A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
KR101700152B1 (ko) 2008-10-03 2017-01-26 이에이 파마 가부시키가이샤 CaSR 효능제
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
AU2012226375B2 (en) 2011-03-10 2017-04-13 Lupin Atlantis Holdings Sa Substituted morpholines as modulators for the calcium sensing receptor
CN103459377B (zh) 2011-03-18 2016-09-07 鲁平有限公司 作为钙敏感受体调变剂的苯并[b][1,4]噁嗪衍生物
BR112014021133B1 (pt) * 2012-02-24 2022-06-28 Lupin Limited Composto e composição farmacêutica

Also Published As

Publication number Publication date
US9163001B2 (en) 2015-10-20
SMT201900506T1 (it) 2019-11-13
US9987249B2 (en) 2018-06-05
TN2014000352A1 (en) 2015-12-21
EA026940B1 (ru) 2017-06-30
AR090135A1 (es) 2014-10-22
IL234252A (en) 2017-02-28
MY171374A (en) 2019-10-10
US20150038546A1 (en) 2015-02-05
PH12014501891B1 (en) 2021-05-05
KR20140135731A (ko) 2014-11-26
BR112014021133B1 (pt) 2022-06-28
EA026940B9 (ru) 2017-11-30
ZA201405990B (en) 2015-11-25
LT2817299T (lt) 2019-09-25
NZ628627A (en) 2017-02-24
AP2014007919A0 (en) 2014-09-30
KR102041154B1 (ko) 2019-11-07
ES2743492T3 (es) 2020-02-19
AU2013223715A1 (en) 2014-08-28
CA2864332C (en) 2020-08-25
JP2015508097A (ja) 2015-03-16
RS59172B1 (sr) 2019-10-31
MX355670B (es) 2018-04-25
SG11201405117SA (en) 2014-09-26
EA201491582A1 (ru) 2014-12-30
WO2013124828A1 (en) 2013-08-29
PH12014501891A1 (en) 2015-02-09
UA112679C2 (uk) 2016-10-10
NI201400094A (es) 2015-03-27
GEP20186911B (en) 2018-10-25
CL2014002218A1 (es) 2015-03-06
PE20142281A1 (es) 2015-01-16
IN2014MN01672A (enExample) 2015-05-29
PL2817299T3 (pl) 2019-12-31
EP2817299A1 (en) 2014-12-31
CY1122017T1 (el) 2020-10-14
GT201400179A (es) 2016-03-01
TW201336831A (zh) 2013-09-16
CR20140424A (es) 2015-01-13
CN104350047A (zh) 2015-02-11
SI2817299T1 (sl) 2019-10-30
MA35937B1 (fr) 2014-12-01
TWI617549B (zh) 2018-03-11
US9598391B2 (en) 2017-03-21
AU2013223715B2 (en) 2017-09-14
CA2864332A1 (en) 2013-08-29
JP6114316B2 (ja) 2017-04-12
MX2014010139A (es) 2015-09-04
US20170209410A1 (en) 2017-07-27
EP2817299B1 (en) 2019-06-12
US20150368222A1 (en) 2015-12-24
CN104350047B (zh) 2017-05-24
PT2817299T (pt) 2019-09-23
CO7160018A2 (es) 2015-01-15
GEAP201813579A (en) 2018-06-25
HUE046172T2 (hu) 2020-02-28
HK1205117A1 (en) 2015-12-11
CU24325B1 (es) 2018-03-13
DOP2014000193A (es) 2017-01-15
BR112014021133A2 (pt) 2018-09-11
DK2817299T3 (da) 2019-09-16
CU20140103A7 (es) 2015-01-29

Similar Documents

Publication Publication Date Title
HRP20191606T1 (hr) Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij
ES2991100T3 (es) Acidos monocarboxílicos y dicarboxílicos de hidrocarburos de cadena larga funcionalizados útiles para la prevención o el tratamiento de enfermedades
ES2210524T3 (es) Derivados de chalcona y medicamentos que los contienen.
JP2017505293A5 (enExample)
JP2015508097A5 (enExample)
RU2015136770A (ru) Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов
RU2019114940A (ru) Лечение катаплексии
JP2004530669A5 (enExample)
JP6227635B2 (ja) 重水素化ベンゾピラン類化合物及びその応用
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
CN103945848A (zh) 被取代的喹唑啉酮的口服即释制剂
EA022815B1 (ru) Антагонист рецептора cgrp
CN105658621A (zh) 4-氨甲基苯甲酸衍生物
RU2013128968A (ru) Соединения, активные в отношении кальций-чувствительного рецептора
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
CS264288B2 (en) Process for preparing new dihydrobenzofuran- and chromat-carboxamides
RU2011102523A (ru) Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
EP4225292A1 (en) Truxillic acid monoester-derivatives as selective fabp5 inhibitors and pharmaceutical compositions and uses thereof
JPWO2006004030A1 (ja) 組織因子産生抑制剤
HRP20130549T4 (hr) Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine
NO20022919L (no) Nye forbindelser
JP2009502775A5 (enExample)
BR112015018442B1 (pt) Compostos de derivados de ciclohexeno biaril- ou heterocíclico biaril-substituídos, composições farmacêuticas e uso
CA2597632C (en) Substituted sulfoxide compounds, methods for preparing the same and use thereof
RU2006126781A (ru) Кислотные производные хинолина и их применение для предупреждения и/или лечения патологий, связанных с гипергликемией